Expression and Regulation of the CC‐Chemokine Ligand 20 During Human Tuberculosis
- 4 December 2007
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 67 (1) , 77-85
Abstract
CC‐chemokine ligand 20 (CCL20), a unique chemokine ligand of CC‐chemokine receptor 6 (CCR6), play roles in various pathologic conditions. However, the characteristic expression profiles of CCL20 during human tuberculosis (TB) have been largely unknown. The present study analyzed the production and regulatory mechanisms of CCL20 in peripheral blood mononuclear cells (PBMC) and monocyte‐derived macrophages (MDM) from active pulmonary TB patients and healthy controls (HC). The 30‐kDa antigen (Ag) of Mycobacterium tuberculosis actively induced the production of CCL20 by human PBMC and MDM. A comparative analysis revealed that the expression of CCL20 protein was prominently up‐regulated in PBMC, MDM, bronchoalveolar lavage fluids (not in sera) from TB patients compared with the corresponding cells or body fluids from HC. Blockade of either tumour necrosis factor‐α or interferon‐γ, but not interleukin‐10, significantly attenuated the CCL20 production. In addition, recombinant CCL20 induced CCR6 expression by CD45RO+ T lymphocytes in a dose‐dependent manner. Furthermore, the expression of CCR6 was significantly increased in CD45RO+ T lymphocytes from TB patients, as compared with those from HC. Pharmacological inhibition studies showed that the 30‐kDa Ag‐induced CCL20 mRNA expression involves mitogen‐activated protein kinases (MAPK; extracellular signal‐regulated kinase 1/2 and p38)‐ and NF‐κB‐dependent signalling. Collectively, the present study demonstrated that TB patients show the up‐regulated expression of CCL20, which is modulated by proinflammatory cytokines, and through MAPK/NF‐κB‐mediated transcriptional mechanisms. The findings suggest important implications of potential roles of CCL20–CCR6 in immunopathogenesis of TB.Keywords
This publication has 41 references indexed in Scilit:
- Life and death in the granuloma: immunopathology of tuberculosisImmunology & Cell Biology, 2007
- Ex Vivo Responses for Interferon‐gamma and Proinflammatory Cytokine Secretion to Low‐Molecular‐Weight Antigen MTB12 of Mycobacterium tuberculosis during Human TuberculosisScandinavian Journal of Immunology, 2006
- Dynamics of cytokine generation in patients with active pulmonary tuberculosisCurrent Opinion in Infectious Diseases, 2003
- The production of tumour necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30-kDa antigen of Mycobacterium tuberculosisClinical and Experimental Immunology, 2003
- Production of Macrophage Inflammatory Protein 3α (MIP-3α) (CCL20) and MIP-3β (CCL19) by Human Peripheral Blood Neutrophils in Response to Microbial PathogensInfection and Immunity, 2003
- CCL20/macrophage inflammatory protein-3? production in LPS-stimulated neutrophils is enhanced by the chemoattractant formyl-methionyl-leucyl-phenylalanine and IFN-? through independent mechanismsEuropean Journal of Immunology, 2002
- Depressed Interleukin-12 (IL-12), but not IL-18, Production in Response to a 30- or 32-Kilodalton Mycobacterial Antigen in Patients with Active Pulmonary TuberculosisInfection and Immunity, 2000
- Dysregulated Production of Interferon-gamma, Interleukin-4 and Interleukin-6 in Early Tuberculosis Patients in Response to Antigen 85B of Mycobacterium tuberculosisScandinavian Journal of Immunology, 2000
- CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic CellsJournal of Experimental Medicine, 1997
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995